Concern arose as a result of deaths from rhabdomyolysis in the United States, 40% of which were associated with prescribing in combination with gemfibrozil. ###>Tire a part de Therapeutics Letter 2001;42:1-3 (www.ti.ubc.ca). Cette chronique comporte une evaluation et une synthese des ouvrages publies jusqu'en septembre 2001.